JeanMarie Guenot is an industrious middle-aged business executive, with an extensive experience in pharmaceutical and biotechnology industry. She has contributed a lot towards the growth of every company that has worked with, both in public and the private sector in the pharmaceutical, business development, corporate and commercial development, and venture capital. Her expertise and interest in building new companies and restructuring the new companies to offer better services have made her a famous woman in the industry.
Jeanmarie started her career life as a team leader and principal scientist, preclinical R&D at Hoffman- La Roche in the year 1993 to 1999. She later became an Associate of Life Sciences at Atlas Venture from 2000 to 2003. From 2003-2008, she joined PDL BioPharma as the vice president, corporate and business development. She was a managing partner for one year in Guenot, LLC. With all the experience and achievements in all these companies, she founded SKS Ocular, where she was the first employee in her company from the year 2009 to 2012.
JeanMarie Guenot licensed the ophthalmic indication for the oncology drug to opisthotic, and she did this through her company SKS Ocular. During her term as the vice president of PDL BioPharma, she licensed mergers, acquisitions, and alliance management for PDLs, R&D and commercial portfolios. Her recent achievement in Ophthalmology has changed the lives of many people, and it was the best for all her contributions in her career life.
Vida Strategic Partners media featured JeanMarie Geunot, through Amphivena Therapeutics, where she is a chief executive officer and the president. In her inventions, Jean discovered drugs that have been of her help to many people, mainly because her drugs are tested to cure metabolic diseases, inflammation, autoimmune diseases, and oncology.
Jeanmarie is an outgoing woman, as her Facebook shows; she mostly posts on her new inventions in pharmaceuticals in her recent tweeted about AMV564, a CD 33/CD3, a drug that is targeting treatment of acute myeloid Leukemia, which is expected to be tested soon.
Learn more about Amphivena Therapeutics CEO on their website: